Tenofovir Disoproxil Fumarate + Rifampin = Unknown or no reaction

Effect on Concentration

Tenofovir Disoproxil Fumarate
No change
Applies within class?
No
Rifampin
No change
Applies within class?
No

Pharmacologic Effects

Tenofovir Disoproxil Fumarate
Effect
N/A
Applies within class?
No
Rifampin
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 19-Jul-2018

Summary

Sources

Tenofovir Disoproxil Fumarate versus Rifampin ^

Study Design

Twenty four healthy adult subjects were enrolled in this multiple dose, open label, single-group, two-period study. All subjects were given tenofovir DF 300 mg daily on days 1 – 10. From days eleven to twenty, the subjects received 300 mg of tenofovir DF with rifampin 600 mg daily. Multiple dose pharmacokinetics of tenofovir DF (day 10 and 20) and rifampin (day 20) were assessed. Pharmacokinetic analysis for 23 patients were available.

Study Results

Point estimates for the mean ratios of tenofovir with rifampin versus tenofovir alone for the AUC, Cmax, and Cmin were 0.88 (0.84 – 0.92), 0.84 (0.78 – 0.9), and 0.85 (0.8 – 0.91) respectively. Similarly, coadministration did not impact rifampin pharmacokinetic values, which were similar to values found in the literature.

Study Conclusions

The authors concluded that coadministration of tenofovir DF with rifampin in patients who have HIV and TB co-infection is accepted and should not require dose adjustments of either medication.

References

Drost JAH, Verweij-van Wissen CPW, Kearney BP, Buffels R, Hekster YA, Burger DM. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrobial Agents And Chemotherapy . 2005; 2: 680-684.